Physician profile
Connie Yang
NPI 1700445814
$4,745.82
in general payments reported to CMS, 2019-2025
19 companies · $442 in 2025
The $442 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.48 · 2022: $165 · 2023: $2,064 · 2024: $2,048 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,553.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $670.40 | 2023-2025 | Rinvoq, Skyrizi |
| Dermavant Sciences, INC. | $541.29 | 2023-2024 | Vtama |
| Merz North America, INC. | $491.29 | 2023-2025 | Xeomin |
| Ucb, INC. | $456.05 | 2023-2024 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $386.56 | 2022-2024 | Sotyktu |
| Janssen Biotech, INC. | $320.54 | 2024 | Tremfya |
| Incyte Corporation | $298.16 | 2023-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $296.20 | 2023-2025 | Dupixent |
| Pfizer INC. | $267.03 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $260.86 | 2023-2024 | Zoryve |
| Novartis Pharmaceuticals Corporation | $188.80 | 2024-2025 | |
| Genzyme Corporation | $177.08 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.78 | 2023 | Spevigo |
| Lilly USA, LLC | $64.81 | 2021-2025 | Ebglyss, Taltz |
| Sun Pharmaceutical Industries INC. | $62.47 | 2023 | Absorica Ld, Winlevi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $28.73 | 2025 | Vtama |
| Leo Pharma INC. | $27.90 | 2024 | Adbry |
| Galderma Laboratories, L.P. | $24.99 | 2025 | Nemluvio |
| Journey Medical Corporation | $18.88 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connie Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.